{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T19:42:18Z","timestamp":1726515738053},"reference-count":11,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["epilepsybehavior.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.yebeh.2015.02.008","type":"journal-article","created":{"date-parts":[[2015,3,30]],"date-time":"2015-03-30T05:50:09Z","timestamp":1427694609000},"page":"234-237","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["A retrospective evaluation of retigabine in patients with cognitive impairment with highly drug-resistant epilepsy"],"prefix":"10.1016","volume":"44","author":[{"given":"Bernd","family":"Huber","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelina","family":"Bocchicchio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2015.02.008_bb0005","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1111\/j.1528-1167.2010.02737.x","article-title":"A graded system to categorize drug-resistant epilepsy","volume":"51","author":"Gomez-Alonso","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2015.02.008_bb0010","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1212\/WNL.0b013e3182194bd3","article-title":"Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy","volume":"76","author":"French","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2015.02.008_bb0015","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1212\/WNL.0b013e3181fd6170","article-title":"Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy","volume":"75","author":"Brodie","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2015.02.008_bb0020","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1212\/01.wnl.0000259034.45049.00","article-title":"Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures","volume":"68","author":"Porter","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2015.02.008_bb0025","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.eplepsyres.2012.05.007","article-title":"Safety and efficacy of ezogabine (retigabine) in adults with refractory partial-onset seizures: interim results from two ongoing open-label studies","volume":"102","author":"Gil-Nagel","year":"2012","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2015.02.008_bb0030","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.seizure.2014.08.001","article-title":"Long term retention of retigabine in a cohort of people with drug resistant epilepsy","volume":"23","author":"Wehner","year":"2014","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2015.02.008_bb0035","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1600-0404.2005.00505.x","article-title":"New antiepileptic drugs in practice\u2014how do they perform in the real world?","volume":"181","author":"Sander","year":"2005","journal-title":"Acta Neurol Scand Suppl"},{"key":"10.1016\/j.yebeh.2015.02.008_bb0040","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1365-2788.2009.01182.x","article-title":"Consensus guidelines into the management of epilepsy in adults with an intellectual disability","volume":"53","author":"Kerr","year":"2009","journal-title":"J Intellect Disabil Res"},{"key":"10.1016\/j.yebeh.2015.02.008_bb0045","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s00115-002-1294-3","article-title":"Effects of topiramate in patients with epilepsy and intellectual deficits","volume":"73","author":"Huber","year":"2002","journal-title":"Nervenarzt"},{"key":"10.1016\/j.yebeh.2015.02.008_bb0050","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/S1059-1311(03)00154-7","article-title":"Efficacy and tolerability of levetiracetam in patients with therapy-resistant epilepsy and learning disabilities","volume":"13","author":"Huber","year":"2004","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2015.02.008_bb0055","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.yebeh.2008.04.021","article-title":"Efficacy and tolerability of pregabalin in patients with difficult-to-treat epilepsy and intellectual disability","volume":"13","author":"Huber","year":"2008","journal-title":"Epilepsy Behav"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505015000566?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505015000566?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,23]],"date-time":"2018-09-23T23:24:58Z","timestamp":1537745098000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505015000566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":11,"alternative-id":["S1525505015000566"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2015.02.008","relation":{},"ISSN":["1525-5050"],"issn-type":[{"type":"print","value":"1525-5050"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A retrospective evaluation of retigabine in patients with cognitive impairment with highly drug-resistant epilepsy","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2015.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}